We hypothesize that a strategy of tubal patency testing during the fertility work-up by HyFoSy results in equal diagnostic outcomes and subsequent management decisions, which lead to similar ongoing pregnancy rates as a strategy of tubal testing…
ID
Bron
Verkorte titel
Aandoening
- Tubal patency testing
- Subfertile women
- Hysterosalpingo-foam sonography (HyFoSy)
- Hysterosalpingography (HSG)
- Cost-effectiveness
- Tubadoorgankelijkheidstest
- Subfertiele vrouwen
- Hysterosalpingo-foam sonografie (HyFoSy)
- Hysterosalpingografie (HSG)
- Kosteneffectiviteit
Ondersteuning
IQ Medical Ventures
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary outcome is ongoing pregnancy rates leading to live birth within 12-months after inclusion.
Achtergrond van het onderzoek
OBJECTIVE: To investigate if tubal patency testing during the fertility work-up by hysterosalpingo-foam sonography (HyFoSy) is more cost-effective compared to hysterosalpingography (HSG).
HYPOTHESIS: We hypothesize that HyFoSy has comparable diagnostic accuracy as HSG for a 50% lower cost.
STUDY DESIGN: We plan a multicenter prospective study of women undergoing tubal patency testing by HyFoSy and HSG in a random order during fertility work-up (RCT1). Women in this study with discordant test results will be randomized for management strategy based on HyFOSy or HSG resulting in a diagnostic laparoscopy with chromopertubation (DLS) or an management based on the prognostic model of Hunault (RCT2). Data will be used in a model based cost-effectiveness analysis.
STUDY POPULATION: Subfertile women scheduled for tubal patency testing.
INTERVENTIONS: Fertility work-up based on HyFoSy.
STANDARD INTERVENTION TO BE COMPARED TO: Fertility work-up based on HSG.
DESIGN: Women will undergo HyFoSy as well as HSG in a random order. Participants with discordant tests results (and therefore apply for different clinical treatments depending on which test was used), will be randomized for for a management strategy based on HyFoSy or HSG resulting in a DLS or a management based on the prognostic model of Hunault. From these data a strategy of outpatient tubal patency testing based on the new technique HyFoSy will be compared with a strategy of tubal patency testing based on HSG.
OUTCOME MEASURES: Ongoing pregnancy rates within 12 month after inclusion. Costs and effectiveness will be analyzed.
SAMPLE SIZE: We propose a non-inferiority effectiveness trial. Under the assumption of a 7% discordance rate between the results of HyFoSy and HSG, we need to randomize 82 women (power 80%) to demonstrate the non-inferiority of HyFoSy (difference < 2%). Basedon the anticipated 7% discordance rate we need to include a total of 1163 women in the study.
COST-EFFECTIVENESS ANALYSIS/BUDGET IMPACT ANALYSIS: The average costs and effectiveness of a strategy of tubal patency testing during fertility work up by HyFoSy or HSG as first line test will be compared. Fertility treatment and pregnancy outcomes will be evaluated after a follow-up of 12 months. Assuming that 20.000 HSGs are made annually in the Netherlands and a difference in cost of €100 in favor of HyFoSy, the budget impact will estimates a saving of over €2 million in case of non-inferiority.
TIME SCHEDULE: month 1-3: preparation; month 4-33 inclusion and follow- up; month 34-36 data analyses and reporting.
Doel van het onderzoek
We hypothesize that a strategy of tubal patency testing during the fertility work-up by HyFoSy results in equal diagnostic outcomes and subsequent management decisions, which lead to similar ongoing pregnancy rates as a strategy of tubal testing by HSG, but tor lower cost.
Onderzoeksopzet
Primary outcome: 12 months after inclusion
Quality of life questionaires: one day before randomisation, and after 3, 6 and 12 months after inclusion.
Onderzoeksproduct en/of interventie
RCT1: Hysterosalpingo-foam sonography (HyFoSy) and hysterosalpingography (HSG) in a random order. In case of discordance test results between HyFoSy and HSG women will be included in RCT 2: management strategy based on HSG or HyFoSy resulting in a diagnostic laparoscopy with chromopertubation or an management according to the prognostic model of Hunault. <1x10^6/ml
Publiek
J. van Rijswijk
Postbus 7057, 1007 MB Amsterdam
Amsterdam
The Netherlands
020-4445277
j.vanrijswijk@vumc.nl
Wetenschappelijk
J. van Rijswijk
Postbus 7057, 1007 MB Amsterdam
Amsterdam
The Netherlands
020-4445277
j.vanrijswijk@vumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Between 18-41 years
- Subfertile for at least one year.
- Valid indication for patency testing in the fertility work-up or before intra-uterine insemination treatment.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Anovulation not responding on ovulation induction
- Endometriosis
- Tubal patency testing in the past
- Severe male factor with a Total motile sperm count <1x106/ml
- Known contrast (iodine) allergy
- If not willing or able to sign the informed consent
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL4587 |
NTR-old | NTR4746 |
CCMO | NL50484.029.14 |
OMON | NL-OMON47620 |